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Background: Although primary angioplasty achieves Thrombolysis In Myocardial Infarction (TIMI) 3 flow
in most patients with ST-elevation myocardial infarction, epicardial recanalization does not guarantee
optimal perfusion in a large proportion of patients. Multivessel disease has been demonstrated to be
associated with impaired survival, however its impact on infarct size has not been largely investigated,
that therefore is the aim of the current study.
Methods: Our population is represented by 827 STEMI patients undergoing primary PCI. Infarct size was
evaluated at 30 days by technetium-99m-sestamibi.
Results: Multivessel disease was observed in 343 patients (41.5%). It was associated with older age (65
[57e74] vs 63 [53e71], p < 0.001), higher rate of previous MI (6.4% vs 2.5%, p ¼ 0.005), longer ischemia
time evaluated as continuous variable (210 [155e280] min vs 196 [145e270] min, p ¼ 0.065) or per-
centage of patients with ischemia time >3 h (63.7% vs 56.4%, p ¼ 0.038), and a trend in more cardiogenic
shock (5.5% vs 2.9%, p ¼ 0.055). Patients with multivessel disease received more often Abciximab (92.1%
vs 88.4%, p < 0.001), Intra-aortic balloon pump (6.4% vs 1.9%, p < 0.001). No differences were observed in
other clinical or angiographic characteristics. In particular, multivessel disease did not affect the rate of
postprocedural TIMI 3 flow (90.9% vs 93.4%, p ¼ 0.18) and ST-segment resolution (52.4% vs 54.9%,
p ¼ 0.48). Multivessel disease did not affect infarct size (12.7% [4.5%e24.9%] vs 12.3% [4%e24.1%],
p ¼ 0.58). Similar results were observed in subanalyses without any significant interaction for each
variable (anterior infarct location (p int ¼ 0.23), gender (p int ¼ 0.9), age (p int ¼ 0.7), diabetes
(p int ¼ 0.15)). The absence of any impact of multivessel disease on infarct size was confirmed when the
analysis was conducted according to the percentage of patients with infarct size above the median, even
after correction for baseline characteristics, such as age, previous MI, ischemia time, use of Gp IIbeIIIa
inhibitors, cardiogenic shock, ischemia time (OR [95% CI] ¼ 1.09 [0.82e1.45], p ¼ 0.58).
Conclusions: This study shows that among STEMI patients undergoing primary PCI multivessel disease
does not affect infarct size.
 2014 Elsevier Ireland Ltd. All rights reserved.1. Introduction
In patients presenting with acute myocardial infarction primary
angioplasty improves survival compared with thrombolysis, due
mainly to a large percentage of restoration of TIMI 3 flow [1,2], with
further improvement in clinical outcomes observed with the usex: þ39 0321 3733407.
novara.it, p.de_luca@libero.it
rved.of new antithrombotic therapies and devices [3e7]. However,
epicardial recanalization does not guarantee optimal myocardial
perfusion, which remains suboptimal in a relatively large propor-
tion of patients [8,9]. In addition, concomitant atherosclerosis in
coronary vessels other than the infarct-related artery (IRA) is
observed in a notable proportion of patients undergoing primary
percutaneous coronary intervention (PCI), ranging from 40% to 50%
[10e12]. The prognostic impact of multivessel coronary artery
disease (CAD) in patients undergoing primary angioplasty has not
been extensively investigated [10e14]. Furthermore, few data exist
Table 1
Demographic and clinical characteristics according to multivessel disease.
Variable Single vessel
disease (n ¼ 484)
Multivessel disease
(n ¼ 343)
p Value
Age 63 [53e71] 65 [57e74] <0.001
Age > 75 ys (%) 17.1 24.2 0.013
Female gender (%) 80.4 77.6 0.325
Smoking (%) 49.6 46.4 0.36
Dyslipidemia (%) 33.5 35.0 0.651
Diabetes (%) 12.8 15.5 0.28
Previous MI (%) 2.5 6.4 0.005
Previous CABG (%) 0.6 1.2 0.398
Previous PTCA (%) 3.1 4.4 0.331
Ischemia time (min) 196 [145e270] 210 [155e280] 0.065
Ischemia time >3 h (%) 56.4 63.7 0.038
Anterior MI (%) 41.5 38.5 0.38
Cardiogenic shock (%) 2.9 5.5 0.055
MI ¼ Myocardial Infarction, CABG ¼ Coronary Artery Bypass Grafting,
PTCA ¼ Percutaneous Transluminal Coronary Angioplasty.
Table 2
Angiographic and procedural characteristics according to multivessel disease.
Variable Single vessel
disease (n ¼ 484)
Multivessel
disease (n ¼ 343)
p Value
Collateral circulation 0.991
RENTROP 0 (%) 87.9 91
RENTROP 1 (%) 9.3 4.2
RENTROP 2 (%) 2.8 3.6
RENTROP 3 (%) 0 1.2
Preprocedural TIMI 3 flow (%) 7.9 8.5 0.765
IRA 0.31
RCA (%) 45.7 44.9
CX (%) 12.8 16.0
Graft (%) 0 0.3
LAD (%) 41.5 38.5
LM (%) 0 0.3
Abciximab (%) 88.4 92.1 <0.001
Stenting (%) 98.3 99.2 0.51
IABP (%) 1.9 6.4 0.001
Postprocedural TIMI 3 flow (%) 93.4 90.9 0.184
Complete ST resolution 54.9 52.4 0.481
DES stenting 7.2 5.3 0.42
TIMI ¼ Thrombolysis in Myocardial Infarction, IRA ¼ Infarct-Related Artery,
RCA ¼ Right Coronary Artery, CX ¼ Circumflex, LAD ¼ Left Anterior Descending
Artery, IABP ¼ Intra-Aortic Balloon Pump, DES ¼ Drug-Eluting Stent.
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well-refined techniques such as nuclear imaging techniques.
Therefore, this is the aim of the current study.
2. Materials and methods
This is a prospective study with the initial population repre-
sented by 894 STEMI patients treated by primary angioplasty, who
were included in randomized trials conducted between 2001 and
2009 that aimed at the evaluation of infarct size at 30 days after
intervention [4,15,16]. A total of 64 patients [16 women (8.7%) and
48 men (7.4%)] were excluded because of death (n ¼ 16), reinfarc-
tion (n ¼ 7), or target vessel revascularization (n ¼ 11) within 30
days from revascularization, or refusal to undergo scintigraphy
(n ¼ 30) and 3 patients undergoing complete revascularization at
the time of primary PCI. Therefore, our final population was rep-
resented by 827 patients.
All patients were admitted within 12 h from symptom onset,
and received at the time of diagnosis aspirin (500 mg intrave-
nously) and heparin (60 IU/kg intravenously), as much as beta-
blockers and nitroglycerine intravenously if not contraindicated,
whereas the decision to provide glycoprotein IIbeIIIa inhibitors was
left at the discretion of the operator at the time of intervention. All
patients were on dual oral antiplatelet therapy (aspirin and clopi-
dogrel or ticlopidine) for at least 4 weeks after stent implantation.
All demographic, clinical, procedural and in-hospital and follow-up
data were collected in a database. Baseline and 30-min post-
procedure, a 12-lead electrocardiogram was recorded using the
same electrocardiograph. The ST-segment elevation was measured
to the nearest 0.5mmat 60ms after the J pointwith the aid of hand-
held calipers. The STR was defined as a reduction in ST-segment
elevation 50% at 30 min after infarct artery recanalization.
2.1. Coronary angiography and mechanical revascularization
Selective coronary angiography was performed in multiple
projections before mechanical reperfusion. Immediately after
diagnostic angiography, percutaneous coronary intervention with
stenting of the infarct-related vessel was performed using standard
material. Multivessel disease was defined as a visually assessed
>70% diameter stenosis of at least one major epicardial artery
beyond the infarct related artery. Successful primary percutaneous
coronary intervention was defined as Thrombolysis In Myocardial
Infarction (TIMI) grade 3 coronary flow in the treated vessel with a
residual stenosis <20% [17]. Angiographic collaterals were evalu-
ated according to Rentrop classification [18].
2.2. Infarct size assessment
Patients underwent evaluation of infarct size at 30 days from the
intervention. As previously described [16], gated single-photon
emission computed tomography (SPECT) acquisition began
60 min after technetium-99m-sestamibi injection (740 MBq), using
a double-head gamma-camera equipped with high-resolution
collimators, 180 rotation arc, 32 projections, 60 s/projection, 8
frames/heart cycle and 64  64 matrices. The studies were recon-
structed using filtered back-projection without attenuation or
scatter correction and realigned along the heart axis. Perfusion
defects were quantified as percentage of LV wall, with the defect
threshold set at 60% of peak uptake [19].
2.3. Statistical analysis
Statistical analysis was performed with the SPSS 17.0 statistical
package. Continuous data were expressed as median [25e75thpercentiles] and categorical data as percentage. The analysis of
variance test (ANOVA) or ManneWhitney U test was appropriately
used for continuous variables, according to the normality of dis-
tribution, as evaluated by the ShapiroeWilk test [20]. The chi-
square test or the Fisher’s exact test was used for categorical vari-
ables. Multiple logistic regression analysis was used to evaluate the
impact of multivessel disease on infarct size after adjustment for
significant (p < 0.1) confounding baseline characteristics.
3. Results
Multivessel disease was observed in 343 patients (41.5%). Pa-
tients’ characteristics are shown in Tables 1 and 2. Multivessel
disease was associated with older age (p < 0.001), higher rate of
previous MI (p ¼ 0.005), longer ischemia time evaluated as
continuous variable (p ¼ 0.065) or percentage of patients with
ischemia time >3 h (p ¼ 0.038), a trend in more cardiogenic shock
(p ¼ 0.055). Patients with multivessel disease received more often
Abciximab (p < 0.001), Intra-aortic balloon pump (p < 0.001). No
differences were observed in other clinical or angiographic vari-
ables. In particular, multivessel disease did not affect post-
procedural TIMI 3 flow (90.9% vs 93.4%, p ¼ 0.18) and ST-segment
resolution (52.4% vs 54.9%, p ¼ 0.48).
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Fig. 1. Bar graphs show the impact of multivessel disease on infarct size. Data are
presented as median [25the75th percentile]. SVD ¼ Single Vessel Disease;
MVD ¼ Multivessel Disease.
Table 3
Multiple logistic regression analysis to investigate the relationship between multi-
vessel disease and infarct size after adjustment for baseline confounding factors,
that were included in block into the model.
Variable Beta SE OR [95% CI] p Value
Age 0.006 0.008 0.99 [0.98e1.01] 0.2
Previous myocardial infarction 0.37 0.44 1.55 [0.75e3.2] 0.23
Cardiogenic shock 0.36 0.32 0.73 [0.36e1.48] 0.38
Gp IIbeIIIa inhibitors 0.24 0.3 0.74 [0.46e1.18] 0.2
Ischemia time >3 h 0.59 0.15 1.8 [1.36e2.4] <0.001
Multivessel disease 0.15 0.11 1.09 [0.82e1.45] 0.58
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(12.7% [4.5%e24.9%] vs 12.3% [4%e24.1%], p ¼ 0.58). The absence
of any impact of multivessel disease on infarct size was confirmed
in subgroup analyses according to infarct location (anterior
STEMI: 15.2% [6%e29.4%] vs 16.1% [5.5%e22.7%], p ¼ 0.81; non-
anterior STEMI: 12.7% [3.3%e21.7%] vs 10.7% [3.1%e21.0%],
p ¼ 0.24; p int ¼ 0.23), gender (female gender: 6.9% [0%e20.8%] vs
5.6% [0%e19.1%], p ¼ 0.89; male gender: 14.0% [6.4%e25.9%] vs
14.0% [5.7%e24.8%], p ¼ 0.48; p int ¼ 0.9), age, (65 years 13.9%
[3.2%e25.3%] vs 15.3% [6.5%e28%], p ¼ 0.76; <65 years: 12.6%
[5.6e24.2%] vs 11.8% [4.0e24.6%], p ¼ 0.63; p int ¼ 0.7), diabetes
(yes: 14.5% [4.0%e22.5%] vs 9.2% [3.9%e24.9%], p ¼ 0.49; no: 12.7%
[4.6%e25.1%] vs 12.8% [4.5%e24%], p ¼ 0.79; p int ¼ 0.15), without
any significant interaction for each variable. The results were
confirmed after the exclusion of patients with previous MI (12.6%
[4.4%e24.9%] vs 12.2% [3.9%e24.2%], p ¼ 0.56).
The absence of any impact of multivessel disease on infarct size
was confirmed when the analysis was performed according to the
percentage of patients with infarct size above the median (Fig. 2),In
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Fig. 2. Bar graphs show the impact of multivessel disease on infarct size (as percentage
of patients above the median). SVD ¼ Single Vessel Disease; MVD ¼ Multivessel
Disease.even after correction for baseline characteristics, such as age, pre-
vious MI, ischemia time, use of Gp IIbeIIIa inhibitors, Cardiogenic
shock (OR [95% CI] ¼ 1.09 [0.82e1.45], p ¼ 0.58) (Table 3).
We finally investigated the impact of concomitant presence
of chronic occlusion on infarct size. As shown in Fig. 3 a non-
significant trend in larger infarct size was observed in patients
with multivessel disease and concomitant presence of chronic
occlusion.
4. Discussion
This is the largest prospective study conducted to date investi-
gating the impact of multivessel disease on infarct size as evaluated
by nuclear technique among STEMI patients undergoing mechan-
ical reperfusion. We did not find any impact of multivessel disease
on myocardial perfusion and scintigraphic infarct size.
Mechanical reperfusion has been demonstrated to improve
survival as compared with thrombolysis in patients with STEMI.
However, clinical outcome remains unsatisfactory in some sub-
groups [21e23]. Multivessel disease is observed in approximately0
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Fig. 3. Bar graphs show the impact of concomitant presence of chronic occlusion in
patients with multivessel disease on infarct size. SVD ¼ Single Vessel Disease;
MVD ¼ Multivessel Disease; CTO ¼ Chronic Total Occlusion.
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with poorer clinical outcomes [10e14].
In a report from the CADILLAC trial [24], Sorajja et al. reported
that the presence of multivessel disease was a powerful indepen-
dent predictor of mortality, even after adjustment for differences in
baseline clinical and angiographic variables. Moreover, the negative
prognostic impact of multivessel disease was not impacted by the
use of stents or glycoprotein IIb/IIIa inhibitors. A significantly better
outcome was observed among patients who received adjunctive
revascularization of the non-IRA. Confirming these findings, data
from the EGYPTcooperation, including patients treated with GP IIb/
IIIa inhibitor and coronary stenting, showed that multivessel dis-
ease was independently associated with impaired myocardial
perfusion and mortality [25]. Similar findings were observed by
Dudek et al. [26]. Few studies have investigated so far the impact of
multivessel disease on infarct size as evaluated by refined imaging
techniques. Tarantini et al. [27] in a population of 288 STEMI
patients undergoing primary angioplasty found that multivessel
disease did not impact myocardial reperfusion and infarct size and
microvascular obstruction as evaluated by the delayed enhance-
ment of cardiac magnetic resonance. The authors found that the
prognostic impact at follow-up was mainly related to a higher
occurrence of reinfarction and coronary revascularization.
This is the largest study conducted so far in order to investigate
the impact of multivessel disease on infarct size as evaluated by
technetium scintigraphy. Confirming the findings by Tarantini et al.
[27], in a population of 827 patients we did not observe any impact
of multivessel disease on infarct size.
Several factors may certainly contribute to explain our findings.
In accordance with previous studies, we found that patients with
multivessel disease have a greater incidence of high-risk baseline
features that may contribute to an adverse prognosis, mainly due to
non-IRA ischemic events. Furthermore, as observed by Eitel et al.
[28], the relation of severe microvascular injury (MVO) to the
extent of infarct expansion (MVO/infarct size) but not infarct size
seems to be a major determinant of prognosis. In fact, MVO/infarct
size is a more powerful predictor for long-term outcome after
STEMI than either parameter alone reflecting a broader degree of
myocardial injury [29]. The extent of infarct size and the develop-
ment of MVO are influenced by diverging parameters, because
MVO is known to be associated with factors beyond the ischemic
damage itself, such as reperfusion injury [29,30].
Despite its high prevalence, few randomized data have been
reported so far on the optimal management of patients with acute
myocardial infarction andmultivessel disease, that have not led to a
clear consensus. A small randomized trial was stopped prematurely
due to slow recruitment [31]. In a recent randomized trial [32], 214
consecutive patients with STEMI and multivessel CAD undergoing
primary angioplasty were randomized before the first angioplasty
to one of three strategies: 1) culprit vessel angioplasty only; 2)
staged revascularization; and 3) simultaneous treatment of non-
IRAs. During a mean follow-up of 2.5 years, 42 (50.0%) patients in
the ‘culprit vessel angioplasty only’ group experienced at least one
major adverse cardiac event, 13 (20.0%) had an event in the staged
revascularization group, and 15 (23.1%) in the simultaneous treat-
ment of non-IRAs group (p < 0.001). In-hospital death, repeat
revascularization and rehospitalization occurred more frequently
in the culprit vessel angioplasty only group (all p < 0.05), while
there was no significant difference in reinfarction among the three
groups.
A subsequentmeta-analysis of randomized and non-randomized
studies [33] showed that complete revascularization in STEMI is safe
and associated with a reduced occurrence of ischemic event mainly
due to less revascularization procedures, without any impact on
mortality.Still controversial is the exact timing of complete revasculari-
zation. A retrospective analysis from the Horizons study [34]
showed that single strategy vs staged PCI was associated with
higher 1-year mortality (9.2% vs 2.3%; p < 0.0001), definite/prob-
able stent thrombosis (5.7% vs 2.3%; p ¼ 0.02), and a trend toward
greater major adverse cardiovascular events (18.1% vs 13.4%;
p ¼ 0.08).
Recently, a relatively small randomized trial [35] including 465
patients, showed that among STEMI patients with multivessel
disease, complete one step revascularization was associated with
improved outcome, with a trend in reduction in mortality. How-
ever, no data were reported on myocardial perfusion and infarct
size. Our study showing no impact of multivessel disease on infarct
size, does not certainly support one step complete revasculariza-
tion. Furthermore, it may be argued that more complex procedures,
such as chronic occlusion, may significantly increase the amount of
contrast media and increase periprocedural complications. Future
randomized trials are certainly needed to evaluate if a complete
revascularization during hospitalization is associated with im-
proved survival, and to establish the right timing (one step or
staged revascularization).
4.1. Study limitations
We assessed infarct size at 1 month after the index infarction
instead of at hospital discharge, as in the majority of previously
published studies. On the other hand, this circumstance should be
more effective in preventing interference of myocardial stunning
with the extent of perfusion defects [36]. The execution of a coro-
nary angiographic control before gated SPECT would have allowed
the exclusion of infarct-related vessel restenosis. Unfortunately, it
was not routinely performed. The availability of outcome data at
1 year follow-up would have improved our results. Unfortunately,
data were not available from all patients and therefore not
included. However, this is a relatively selected cohort of patients,
being included in randomized trials and being 30-day survivors.
Due to the small number of patients (n ¼ 26), we cannot certainly
exclude a potential impact of the presence of a chronic occlusion
on infarct size among patients with multivessel disease. SPECT
may potentially have problems to discriminate older infarcts in
boundary regions. In our study, a higher occurrence of previous
NSTEMI was observed among patients with multivessel disease.
However, due to the small proportion (4.1%), this issue is not ex-
pected to have relevant impact on our results, as confirmed by the
analysis after the exclusion of these patients. The absence of a
significant association between multivessel disease and cardio-
genic shock at admissionmay be due to a potential selection bias, as
much as to the relatively small sample size [37,38]. Finally, we
classified our population according to the number of diseased
vessels. However, we did not take into account the potential dif-
ference in extension of jeopardized areas.
5. Conclusions
This study showed that among STEMI patients undergoing pri-
mary angioplasty, smoking does not affect scintigraphic infarct size.
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